DexCom Inc (DXCM) stock
DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 22/3031% below fair value
$82.52+0.48 (+0.59%)
Close on Nov 18, 2026Market cap $30.78BP/E 32.5Yield –
DexCom operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
DexCom's operating income for the twelve months ending Sep 30, 2026 was $1.22B, up 57.4% year over year. For fiscal 2025 it was $911.80M, up 52.0% from the year before. The highest annual figure on record is $911.80M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $911.80M | +52.0% |
| FY2024 | Dec 31, 2024 | $600.00M | +0.4% |
| FY2023 | Dec 31, 2023 | $597.70M | +52.8% |
| FY2022 | Dec 31, 2022 | $391.20M | +47.2% |
| FY2021 | Dec 31, 2021 | $265.80M | -11.3% |
| FY2020 | Dec 31, 2020 | $299.50M | +110.5% |
| FY2019 | Dec 31, 2019 | $142.30M | – |
| FY2018 | Dec 31, 2018 | -$186.30M | – |
| FY2017 | Dec 31, 2017 | -$42.50M | – |
| FY2016 | Dec 31, 2016 | -$63.90M | – |
| FY2015 | Dec 31, 2015 | -$57.10M | – |
| FY2014 | Dec 31, 2014 | -$21.50M | – |
| FY2013 | Dec 31, 2013 | -$28.90M | – |
| FY2012 | Dec 31, 2012 | -$55.70M | – |
| FY2011 | Dec 31, 2011 | -$44.80M | – |
| FY2010 | Dec 31, 2010 | -$45.30M | – |
| FY2009 | Dec 31, 2009 | -$45.83M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $327.20M | +34.9% |
| Q2 FY2026 | Jun 30, 2026 | $318.30M | +49.7% |
| Q1 FY2026 | Mar 31, 2026 | $255.30M | +90.9% |
| Q4 FY2025 | Dec 31, 2025 | $323.00M | +71.0% |
| Q3 FY2025 | Sep 30, 2025 | $242.50M | +59.5% |
| Q2 FY2025 | Jun 30, 2025 | $212.60M | +34.6% |
| Q1 FY2025 | Mar 31, 2025 | $133.70M | +32.2% |
| Q4 FY2024 | Dec 31, 2024 | $188.90M | -12.9% |
| Q3 FY2024 | Sep 30, 2024 | $152.00M | -26.0% |
| Q2 FY2024 | Jun 30, 2024 | $158.00M | +23.3% |
| Q1 FY2024 | Mar 31, 2024 | $101.10M | +114.2% |
| Q4 FY2023 | Dec 31, 2023 | $216.90M | +73.0% |
| Q3 FY2023 | Sep 30, 2023 | $205.50M | +39.3% |
| Q2 FY2023 | Jun 30, 2023 | $128.10M | +66.4% |
| Q1 FY2023 | Mar 31, 2023 | $47.20M | +14.3% |
| Q4 FY2022 | Dec 31, 2022 | $125.40M | +20800.0% |
| Q3 FY2022 | Sep 30, 2022 | $147.50M | +24.7% |
| Q2 FY2022 | Jun 30, 2022 | $77.00M | -23.8% |
| Q1 FY2022 | Mar 31, 2022 | $41.30M | -10.0% |
| Q4 FY2021 | Dec 31, 2021 | $600.00K | -99.4% |
| Q3 FY2021 | Sep 30, 2021 | $118.30M | +25.7% |
| Q2 FY2021 | Jun 30, 2021 | $101.00M | +49.0% |
| Q1 FY2021 | Mar 31, 2021 | $45.90M | +36.6% |
| Q4 FY2020 | Dec 31, 2020 | $104.00M | +2.5% |
| Q3 FY2020 | Sep 30, 2020 | $94.10M | +68.0% |
| Q2 FY2020 | Jun 30, 2020 | $67.80M | – |
| Q1 FY2020 | Mar 31, 2020 | $33.60M | – |
| Q4 FY2019 | Dec 31, 2019 | $101.50M | – |
| Q3 FY2019 | Sep 30, 2019 | $56.00M | +302.9% |
| Q2 FY2019 | Jun 30, 2019 | -$800.00K | – |
| Q1 FY2019 | Mar 31, 2019 | -$14.40M | – |
| Q4 FY2018 | Dec 31, 2018 | -$164.60M | -1471.7% |
| Q3 FY2018 | Sep 30, 2018 | $13.90M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.90M | – |
| Q1 FY2018 | Mar 31, 2018 | -$30.70M | – |
| Q4 FY2017 | Dec 31, 2017 | $12.00M | – |
| Q3 FY2017 | Sep 30, 2017 | -$500.00K | – |
| Q2 FY2017 | Jun 30, 2017 | -$13.60M | – |
| Q1 FY2017 | Mar 31, 2017 | -$40.40M | – |
| Q4 FY2016 | Dec 31, 2016 | -$6.10M | – |
See a number that looks wrong?